Techniques for implementing continuous glucose monitoring in primary care

Techniques for implementing continuous glucose monitoring in primary care

Meet the faculty

Jennifer Green, MD

Program Director

Jennifer Green, MD

Duke University, Durham, NC

Dr. Jennifer Green is a professor of medicine in the division of endocrinology at Duke University, and a faculty member of the Duke Clinical Research Institute. Her research has focused upon strategies to treat diabetes and reduce the risks of cardiovascular, kidney and other diabetes-related complications.  Her work with the DCRI has included protocol development, oversight of adjudication committees, and clinical and operational leadership for several large, international trials designed to determine the cardiovascular effects of glucose-lowering medications (TECOS, EXSCEL, and Harmony Outcomes). She currently serves as US coordinating center PI and US national representative for the EMPA-Kidney trial of empagliflozin therapy in patients with chronic kidney disease. EMPA-Kidney found that empagliflozin reduced the risk of a composite cardiorenal outcome in a broad spectrum of individuals with chronic kidney disease, with or without diabetes: a long term follow-up study of the participants is ongoing.

Dr. Green is also part of the multidisciplinary leadership team for COORDINATE-Diabetes, a trial which was successful in increasing delivery of several guideline-based therapies (including high intensity statin, ACEi/ARB, and SGLT2i or GLP-1RA) to patients with T2D and ASCVD who received care in cardiology clinics across the US. She is now leading an innovative, centralized, siteless study of an intervention to reduce the risk of future diabetic foot ulceration which will be conducted using an EHR-linked software platform to assess clinical outcomes.

Dr. Green has concluded three years of service as a member of the American Diabetes Association’s (ADA) Professional Practice Committee, which publishes the organization’s annual Standards of Care in Diabetes. She is now a member of the international ADA-EASD writing group which recently revised a joint consensus statement on the management of hyperglycemia in type 2 diabetes.

Disclosures:

  • Grant/Research Support: Merck, Roche, Lilly, Boehringer Ingelheim, Bluedrop
  • Consultant/Advisory Board: AstraZeneca, NovoNordisk, Pfizer, Bayer, Anji, Boehringer Ingelheim, Valo, Lilly, Vertex
Rozalina McCoy, MD, MS

Rozalina McCoy, MD, MS

University of Maryland School of Medicine, Baltimore, MD

Dr. Rozalina McCoy is an Associate Professor in the Department of Medicine’s Division of Endocrinology, Diabetes, and Nutrition, where she also serves as the Associate Division Chief for Clinical Research, and the Director of the Precision Medicine and Population Health Program within the University of Maryland Institute for Health Computing.

Dr. McCoy is a physician scientist who – through clinical care, research, and advocacy – is dedicated to improving the quality, accessibility, and sustainability of diabetes care. She is particularly interested in understanding and addressing the structural factors that lead to suboptimal care and poor health with the goal of developing precision medicine tools and patient-centered care delivery models that improve health and wellbeing, while supporting the sustainability of the healthcare system. Dr. McCoy’s methodologic expertise is in the use of real-world data, including secondary analyses of administrative claims and electronic health record data; pragmatic point-of-care clinical trials; and population health research. She has been funded by the National Institutes of Health, the Patient-Centered Outcomes Research Institute, and the American Diabetes Association, and has authored over 160 peer-reviewed manuscripts.

Dr. McCoy is passionate about caring for patients and serving her community, training the next generation of clinicians and applied researchers, and driving practice transformation to achieve better health outcomes with greater efficiency and lower cost. During her time at Mayo Clinic (2015-2023), she led multiple efforts to improve care delivery through team-based primary care and community paramedicine. Dr. McCoy joined the University of Maryland family in August 2023 and is excited to work with faculty, students, and staff across the University of Maryland Baltimore, University of Maryland College Park (where she has an adjunct faculty position in the Department of Health Policy and Management of the University of Maryland School of Public Health), University of Maryland Baltimore County, University of Maryland Medical System (UMMS), and communities across Maryland to improve health through research, practice transformation, service, and education.

Disclosures:

  • Consultant/Advisory Board: Emmi (Wolters Kluwer)
Eugene E. Wright, Jr., MD

Eugene E. Wright, Jr., MD

Duke University Medical Center, Durham, NC

Dr. Eugene E. Wright, Jr. holds an appointment as Consulting Associate in the Department of Medicine of Duke University Medical Center. Dr. Wright has over 40 years of clinical experience as a private practitioner, academic clinician and educator, medical administrator, a rural physician in southeastern NC and a volunteer physician. From 2000 to 2013, he served in several roles within the Cape Fear Valley Health System including Medical Director for Primary Care and Speciality Services and Chief Medical Officer for the health system. He currently works with the South Piedmont AHEC in Performance Improvement since 2018.

Dr. Wright serves as an Associate Editor of Clinical Diabetes, and has served on several advisory and editorial boards to include Diabetes Technology and Therapeutics and as a content reviewer for UpToDate. He served as the inaugural chair of the ADA Primary Care Interest Group, as a member of the ADA/AHA Know Diabetes by Heart Science Advisory Group and in several leadership roles with the ADA Clinical Conference. Dr. Wright has published numerous articles on diabetes diagnosis, treatments and management and has given presentations at national and international meetings on new treatments and technology for diabetes.

Dr. Wright has an undergraduate BSE in Electrical Engineering from Princeton University (1973) and a medical degree from Duke University School of Medicine (1978). He completed his internship and residency in Internal Medicine at Duke University Hospital in 1981.

Disclosures:

  • Speakers Bureau: Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Eli Lilly, Sanofi
  • Consultant/Advisory Board: Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Eli Lilly, Embecta, Sanofi, Medtronic